News and Treatment Updates | Page 3 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

News and Treatment Updates

  1. Home
  2. Patients and Families

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

New CEO appointed to lead the Aplastic Anemia and MDS International Foundation

Originally Published: 11/30/2022
Article Source: Press Release
FOR IMMEDIATE RELEASE The Aplastic Anemia and MDS International Foundation 401 N. Washington Street, Suite 430 Rockville, MD 20850 U.S.A. New CEO appointed to lead the Aplastic Anemia and MDS International Foundation Bethesda, MD, (November 30, 2022) -- The Board of Directors of the Aplastic Anemia and MDS International Foundation (AAMDSIF) is pleased to announce the appointment of Brad A. Wong as Chief Executive Officer and Executive Director.  Starting December 5, 2022, Mr. Wong will take the reins of the world's leading nonprofit health organization dedicated to supporting patients and...

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Originally Published: 09/12/2022
Article Source: External Web Content
Key Points Itacitinib monotherapy is as effective as systemic corticosteroids for the treatment of low risk acute GVHD. Itacitinib monotherapy resulted in fewer serious infections compared to systemic corticosteroids. The standard primary treatment for acute graft vs host disease (GVHD) requires prolonged, high dose systemic corticosteroids (SCS) that delay reconstitution of the immune system. We used validated clinical and biomarker staging criteria to identify a group of patients with low risk (LR) GVHD that is very likely to respond to SCS. We hypothesized that itacitinib, a selective...

Summer MDS Update 2022

Originally Published: 08/18/2022
Article Source: MDS Update

Press Release Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Originally Published: 08/01/2022
Article Source: External Web Content
BOSTON--(BUSINESS WIRE)--Aug. 1, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug...

Patients With MPNs Must Be Honest About Their Symptoms, Says Expert

Originally Published: 06/20/2022
Article Source: External Web Content
It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center. Because patients with essential thrombocythemia (ET) or polycythemia vera (PV) — rare types of blood cancers known as myeloproliferative neoplasms (MPNs) — experience a range of symptoms that can significantly impact their quality of life, it’s important that patients communicate what they’re experiencing with their health care team. Symptoms may include fatigue, symptoms...

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

Originally Published: 06/02/2022
Article Source: External Web Content
June 2, 2022 - Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant – - Omidubicel has Orphan Drug Designation and Breakthrough Therapy Designation - BOSTON--(BUSINESS WIRE)--Jun. 2, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced completion of the rolling Biologics License...

Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia

Originally Published: 05/25/2022
Article Source: External Web Content
BOSTON, May 25, 2022  – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed...

Spring MDS Update 2022

Originally Published: 05/01/2022
Article Source: MDS Update

The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator

Originally Published: 03/28/2022
Article Source: External Web Content
PURPOSE: Patients who have cancer have leveraged the Internet to gain a better understanding of their disease and connect across geographic boundaries with others facing the same challenges. Online cancer communities have developed into resources that highlight new research and evolving care pathways. Combined with increasing health literacy and social media, they have enabled some patients to become experts in their cancer. This combination of empowerment and expertise describes the new “e-patients.” Article continues at link.

Living in an online world: Social media experiences of adolescents and young adults with cancer

Originally Published: 03/16/2022
Article Source: External Web Content
Abstract Background Despite widespread use, little is known about how adolescents and young adults (AYA) with cancer use social media (SM). This research characterized use and self-reported SM experiences among AYA with cancer. Procedure AYA, aged 12-26 years, receiving cancer care completed a mixed-methods survey regarding SM experiences. Clinical information was obtained from the electronic medical record. Data were analyzed with descriptive statistics, t tests, and qualitative content analysis. Results Thirty-nine AYA with average age 16 (SD = 3.2) years participated. Most were Caucasian...